PHARMARON BEIJING H YC1
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more
PHARMARON BEIJING H YC1 (17Q1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PHARMARON BEIJING H YC1 (17Q1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PHARMARON BEIJING H YC1 - Net Assets Trend (None–None)
This chart illustrates how PHARMARON BEIJING H YC1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PHARMARON BEIJING H YC1 (None–None)
The table below shows the annual net assets of PHARMARON BEIJING H YC1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PHARMARON BEIJING H YC1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PHARMARON BEIJING H YC1 Competitors by Market Cap
The table below lists competitors of PHARMARON BEIJING H YC1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
InPost S.A
PINK:INPOF
|
$2.62 Billion |
|
21Vianet Group Inc
F:217A
|
$2.62 Billion |
|
Banco del Bajío S.A. Institución de Banca Múltiple
PINK:BBAJF
|
$2.62 Billion |
|
JD Logistics Inc
PINK:JDLGF
|
$2.62 Billion |
|
ALK-Abelló A/S
PINK:AKBLF
|
$2.61 Billion |
|
BOCHGR
AT:BOCHGR
|
$2.61 Billion |
|
Ultra Clean Holdings Inc
NASDAQ:UCTT
|
$2.61 Billion |
|
Thai Beverage Public Company Limited
PINK:TBVPF
|
$2.61 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PHARMARON BEIJING H YC1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PHARMARON BEIJING H YC1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PHARMARON BEIJING H YC1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PHARMARON BEIJING H YC1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PHARMARON BEIJING H YC1 (17Q1) | €- | N/A | N/A | $2.62 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |